|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Curado MP and Hashibe M: Recent changes in
the epidemiology of head and neck cancer. Curr Opin Oncol.
21:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scully C and Bagan J: Oral squamous cell
carcinoma overview. Oral Oncol. 45:301–308. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schwam ZG and Judson BL: Improved
prognosis for patients with oral cavity squamous cell carcinoma:
Analysis of the National Cancer Database 1998-2006. Oral Oncol.
52:45–51. 2016. View Article : Google Scholar
|
|
5
|
Dumontet C and Jordan MA:
Microtubule-binding agents: A dynamic field of cancer therapeutics.
Nat Rev Drug Discov. 9:790–803. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Silverman JA, Reynolds L and Deitcher SR:
Pharmacokinetics and pharmacodynamics of vincristine sulfate
liposome injection (VSLI) in adults with acute lymphoblastic
leukemia. J Clin Pharmacol. 53:1139–1145. 2013.PubMed/NCBI
|
|
7
|
Yan Z, Zhu ZL, Qian ZZ, Hu G, Wang HQ, Liu
WH and Cheng G: Pharmacokinetic characteristics of vincristine
sulfate liposomes in patients with advanced solid tumors. Acta
Pharmacol Sin. 33:852–858. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Olasz L, Orsi E, Marko T and Szalma J:
Induction chemotherapy response and recurrence rates in correlation
with N0 or N+ stage in oral squamous cell cancer (OSCC). Cancer
Metastasis Rev. 29:607–611. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Villanueva J and Herlyn M: Melanoma and
the tumor microenvi-ronment. Curr Oncol Rep. 10:439–446. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen JC, Lee IN, Huang C, Wu YP, Chung CY,
Lee MH, Lin MH and Yang JT: Valproic acid-induced amphiregulin
secretion confers resistance to temozolomide treatment in human
glioma cells. BMC Cancer. 19:7562019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Milman N, Ginini L and Gil Z: Exosomes and
their role in tumorigenesis and anticancer drug resistance. Drug
Resist Updat. 45:1–12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siveen KS, Raza A, Ahmed EI, Khan AQ,
Prabhu KS, Kuttikrishnan S, Mateo JM, Zayed H, Rasul K, Azizi F, et
al: The role of extracellular vesicles as modulators of the tumor
microenvironment, metastasis and drug resistance in colorectal
cancer. Cancers (Basel). 11. pii: E746. 2019, View Article : Google Scholar
|
|
13
|
Wilson TR, Fridlyand J, Yan Y, Penuel E,
Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al:
Widespread potential for growth-factor-driven resistance to
anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Straussman R, Morikawa T, Shee K,
Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J,
Frederick DT, et al: Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature.
487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Acharyya S, Oskarsson T, Vanharanta S,
Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N,
Seshan VE, et al: A CXCL1 paracrine network links cancer
chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berasain C and Avila MA: Amphiregulin.
Semin Cell Dev Biol. 28:31–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Willmarth NE and Ethier SP: Autocrine and
juxtacrine effects of amphiregulin on the proliferative, invasive,
and migratory properties of normal and neoplastic human mammary
epithelial cells. J Biol Chem. 281:37728–37737. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berasain C, Castillo J, Perugorria MJ,
Prieto J and Avila MA: Amphiregulin: A new growth factor in
hepatocarcinogenesis. Cancer Lett. 254:30–41. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yotsumoto F, Fukami T, Yagi H, Funakoshi
A, Yoshizato T, Kuroki M and Miyamoto S: Amphiregulin regulates the
activation of ERK and Akt through epidermal growth factor receptor
and HER3 signals involved in the progression of pancreatic cancer.
Cancer Sci. 101:2351–2360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuramochi H, Nakajima G, Kaneko Y,
Nakamura A, Inoue Y, Yamamoto M and Hayashi K: Amphiregulin and
Epiregulin mRNA expression in primary colorectal cancer and
corresponding liver metastases. BMC Cancer. 12:882012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen JC, Huang C, Lee IN, Wu YP and Tang
CH: Amphiregulin enhances cell migration and resistance to
doxorubicin in chon-drosarcoma cells through the MAPK pathway. Mol
Carcinog. 57:1816–1824. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tokunaga S, Nagano T, Kobayashi K,
Katsurada M, Nakata K, Yamamoto M, Tachihara M, Kamiryo H, Yokozaki
H and Nishimura Y: Amphiregulin as a novel resistance factor for
amru-bicin in lung cancer cells. Anticancer Res. 37:2225–2231.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haab BB: Antibody arrays in cancer
research. Mol Cell Proteomics. 4:377–383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsai ST, Yang KY, Jin YT, Lin YC, Chang MT
and Wu LW: Amphiregulin as a tumor promoter for oral squamous cell
carcinoma: Involvement of cyclooxygenase 2. Oral Oncol. 42:381–390.
2006. View Article : Google Scholar
|
|
25
|
Zhang J, Wang Y, Chen X, Zhou Y, Jiang F,
Chen J, Wang L and Zhang WF: MiR-34a suppresses amphiregulin and
tumor metastatic potential of head and neck squamous cell carcinoma
(HNSCC). Oncotarget. 6:7454–7469. 2015.PubMed/NCBI
|
|
26
|
Gao J, Ulekleiv CH and Halstensen TS:
Epidermal growth factor (EGF) receptor-ligand based molecular
staging predicts prognosis in head and neck squamous cell carcinoma
partly due to deregulated EGF-induced amphiregulin expression. J
Exp Clin Cancer Res. 35:1512016. View Article : Google Scholar
|
|
27
|
Wang S, Zhang Y, Wang Y, Ye P, Li J, Li H,
Ding Q and Xia J: Amphiregulin confers regulatory T cell
suppressive function and tumor invasion via the EGFR/GSK-3β/Foxp3
Axis. J Biol Chem. 291:21085–21095. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mishra R: Glycogen synthase kinase 3 beta:
Can it be a target for oral cancer. Mol Cancer. 9:1442010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Addison CL, Ding K, Zhao H, Le Maître A,
Goss GD, Seymour L, Tsao MS, Shepherd FA and Bradbury PA: Plasma
transforming growth factor alpha and amphiregulin protein levels in
NCIC Clinical Trials Group BR.21. J Clin Oncol. 28:5247–5256. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hsu YL, Huang MS, Cheng DE, Hung JY, Yang
CJ, Chou SH and Kuo PL: Lung tumor-associated dendritic
cell-derived amphireg-ulin increased cancer progression. J Immunol.
187:1733–1744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McBryan J, Howlin J, Napoletano S and
Martin F: Amphiregulin: Role in mammary gland development and
breast cancer. J Mammary Gland Biol Neoplasia. 13:159–169. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
D'Antonio A, Losito S, Pignata S, Grassi
M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson
GR, et al: Transforming growth factor alpha, amphiregulin and
cripto-1 are frequently expressed in advanced human ovarian
carcinomas. Int J Oncol. 21:941–948. 2002.PubMed/NCBI
|
|
33
|
Freimann S, Ben-Ami I, Hirsh L, Dantes A,
Halperin R and Amsterdam A: Drug development for ovarian
hyper-stimulation and anti-cancer treatment: Blocking of
gonadotropin signaling for epiregulin and amphiregulin
biosynthesis. Biochem Pharmacol. 68:989–996. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Castillo J, Erroba E, Perugorria MJ,
Santamaría M, Lee DC, Prieto J, Avila MA and Berasain C:
Amphiregulin contributes to the transformed phenotype of human
hepatocellular carcinoma cells. Cancer Res. 66:6129–6138. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ebert M, Yokoyama M, Kobrin MS, Friess H,
Lopez ME, Büchler MW, Johnson GR and Korc M: Induction and
expression of amphiregulin in human pancreatic cancer. Cancer Res.
54:3959–3962. 1994.PubMed/NCBI
|
|
36
|
Yamada M, Ichikawa Y, Yamagishi S,
Momiyama N, Ota M, Fujii S, Tanaka K, Togo S, Ohki S and Shimada H:
Amphiregulin is a promising prognostic marker for liver metastases
of colorectal cancer. Clin Cancer Res. 14:2351–2356. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gidding CE, Kellie SJ, Kamps WA and de
Graaf SS: Vincristine revisited. Crit Rev Oncol Hematol.
29:267–287. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Corbett R, Pinkerton R, Pritchard J,
Meller S, Lewis I, Kingston J and McElwain T: Pilot study of
high-dose vincristine, etoposide, carboplatin and melphalan with
autologous bone marrow rescue in advanced neuroblastoma. Eur J
Cancer. 28A:1324–1328. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gordon SJ, Pearson AD, Reid MM and Craft
AW: Toxicity of single-day high-dose vincristine, melphalan,
etoposide and carboplatin consolidation with autologous bone marrow
rescue in advanced neuroblastoma. Eur J Cancer. 28A:1319–1323.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xi GM, Sun B, Jiang HH, Kong F, Yuan HQ
and Lou HX: Bisbibenzyl derivatives sensitize vincristine-resistant
KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
Bioorg Med Chem. 18:6725–6733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yan YX, Li WZ, Huang YQ and Liao WX: The
COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral
cancer cell lines to Vincristine by down-regulating P-glycoprotein
expression and function. Prostaglandins Other Lipid Mediat.
97:29–35. 2012. View Article : Google Scholar
|
|
42
|
Yuan Z, Wang H, Hu Z, Huang Y, Yao F, Sun
S and Wu B: Quercetin inhibits proliferation and drug resistance in
KB/VCR oral cancer cells and enhances its sensitivity to
vincristine. Nutr Cancer. 67:126–136. 2015. View Article : Google Scholar
|
|
43
|
Canto LMD, Cury SS, Barros-Filho MC,
Kupper BEC, Begnami MDFS, Scapulatempo-Neto C, Carvalho RF, Marchi
FA, Olsen DA, Madsen JS, et al: Locally advanced rectal cancer
transcriptomic-based secretome analysis reveals novel biomarkers
useful to identify patients according to neoadjuvant
chemoradiotherapy response. Sci Rep. 9:87022019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin M, Zhou C, He S, Yu H, Guo T, Ye J,
Feng X and Bian X: The research advances of exosomes in esophageal
cancer. Biomark Med. 13:685–695. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Osborne DG, Domenico J, Luo Y, Reid AL,
Amato C, Zhai Z, Gao D, Ziman M, Dinarello CA, Robinson WA and
Fujita M: Interleukin-37 is highly expressed in regulatory T cells
of melanoma patients and enhanced by melanoma cell secretome. Mol
Carcinog. 58:1670–1679. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Obenauf AC, Zou Y, Ji AL, Vanharanta S,
Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, et al:
Therapy-induced tumour secretomes promote resistance and tumour
progression. Nature. 520:368–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Amrutkar M, Aasrum M, Verbeke CS and
Gladhaug IP: Secretion of fibronectin by human pancreatic stellate
cells promotes chemoresistance to gemcitabine in pancreatic cancer
cells. BMC Cancer. 19:5962019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kulasingam V and Diamandis EP: Strategies
for discovering novel cancer biomarkers through utilization of
emerging technologies. Nat Clin Pract Oncol. 5:588–599. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
May M: From cells, secrets of the
secretome leak out. Nat Med. 15:8282009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang X, Masri S, Phung S and Chen S: The
role of amphiregulin in exemestane-resistant breast cancer cells:
Evidence of an auto-crine loop. Cancer Res. 68:2259–2265. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen JC, Chen YJ, Lin CY, Fong YC, Hsu CJ,
Tsai CH, Su JL and Tang CH: Amphiregulin enhances alpha6beta1
integrin expression and cell motility in human chondrosarcoma cells
through Ras/Raf/MEK/ERK/AP-1 pathway. Oncotarget. 6:11434–11446.
2015.PubMed/NCBI
|
|
52
|
Kakiuchi S, Daigo Y, Ishikawa N, Furukawa
C, Tsunoda T, Yano S, Nakagawa K, Tsuruo T, Kohno N, Fukuoka M, et
al: Prediction of sensitivity of advanced non-small cell lung
cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:3029–3043.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lorente M, Carracedo A, Torres S, Natali
F, Egia A, Hernández-Tiedra S, Salazar M, Blázquez C, Guzmán M and
Velasco G: Amphiregulin is a factor for resistance of glioma cells
to cannabinoid-induced apoptosis. Glia. 57:1374–1385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, et
al: Increases of amphiregulin and transforming growth factor-alpha
in serum as predictors of poor response to gefitinib among patients
with advanced non-small cell lung cancers. Cancer Res.
65:9176–9184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kao SY and Lim E: An overview of detection
and screening of oral cancer in Taiwan. Chin J Dent Res. 18:7–12.
2015.PubMed/NCBI
|
|
56
|
Chiang WF, Liu SY, Yen CY, Lin CN, Chen
YC, Lin SC and Chang KW: Association of epidermal growth factor
receptor (EGFR) gene copy number amplification with neck lymph node
metastasis in areca-associated oral carcinomas. Oral Oncol.
44:270–276. 2008. View Article : Google Scholar
|
|
57
|
Huang SF, Chuang WY, Chen IH, Liao CT,
Wang HM and Hsieh LL: EGFR protein overexpression and mutation in
areca quid-associated oral cavity squamous cell carcinoma in
Taiwan. Head Neck. 31:1068–1077. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Huang SF, Chien HT, Cheng SD, Chuang WY,
Liao CT and Wang HM: EGFR copy number alterations in primary
tumors, metastatic lymph nodes, and recurrent and multiple primary
tumors in oral cavity squamous cell carcinoma. BMC Cancer.
17:5922017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Huang SF, Chien HT, Chuang WY, Lai CH,
Cheng SD, Liao CT and Wang HM: Epidermal growth factor receptor
intron-1 CA repeat polymorphism on protein expression and clinical
outcome in Taiwanese oral squamous cell carcinoma. Sci Rep.
7:49632017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rubin Grandis J, Melhem MF, Gooding WE,
Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ: Levels of
TGF-alpha and EGFR protein in head and neck squamous cell carcinoma
and patient survival. J Natl Cancer Inst. 90:824–832. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Harding J and Burtness B: Cetuximab: An
epidermal growth factor receptor chemeric human-murine monoclonal
antibody. Drugs Today (Barc). 41:107–127. 2005. View Article : Google Scholar
|
|
62
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Doble BW and Woodgett JR: GSK-3: Tricks of
the trade for a multi-tasking kinase. J Cell Sci. 116:1175–1186.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Luo J: Glycogen synthase kinase 3beta
(GSK3beta) in tumorigen-esis and cancer chemotherapy. Cancer Lett.
273:194–200. 2009. View Article : Google Scholar
|
|
66
|
Domoto T, Pyko IV, Furuta T, Miyashita K,
Uehara M, Shimasaki T, Nakada M and Minamoto T: Glycogen synthase
kinase-3β is a pivotal mediator of cancer invasion and resistance
to therapy. Cancer Sci. 107:1363–1372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Maqbool M and Hoda N: GSK3 inhibitors in
the therapeutic development of diabetes, cancer and
neurodegeneration: Past, present and future. Curr Pharm Des.
23:4332–4350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Walz A, Ugolkov A, Chandra S, Kozikowski
A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD and Mazar AP:
Molecular pathways: Revisiting glycogen synthase kinase-3β as a
target for the treatment of cancer. Clin Cancer Res. 23:1891–1897.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Pramanik KK, Nagini S, Singh AK, Mishra P,
Kashyap T, Nath N, Alam M, Rana A and Mishra R: Glycogen synthase
kinase-3β mediated regulation of matrix metalloproteinase-9 and its
involvement in oral squamous cell carcinoma progression and
invasion. Cell Oncol (Dordr). 41:47–60. 2018. View Article : Google Scholar
|
|
70
|
Matsuo FS, Andrade MF, Loyola AM, da Silva
SJ, Silva MJB, Cardoso SV and de Faria PR: Pathologic significance
of AKT, mTOR, and GSK3β proteins in oral squamous cell
carcinoma-affected patients. Virchows Arch. 472:983–997. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Huang GL, Shen DY, Cai CF, Zhang QY, Ren
HY and Chen QX: β-escin reverses multidrug resistance through
inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
World J Gastroenterol. 21:1148–1157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ugolkov A, Gaisina I, Zhang JS, Billadeau
DD, White Kozikowski A, Jain S, Cristofanilli M, Giles F,
O'Halloran T, et al: GSK-3 inhibition overcomes chemoresistance in
human breast cancer. Cancer Lett. 380:384–392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ugolkov A, Qiang W, Bondarenko G, Procissi
D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H,
O'Halloran T, et al: Combination treatment with the GSK-3 inhibitor
9-ING-41 and CCNU cures orthotopic chemoresistant glioblastoma in
patient-derived xenograft models. Transl Oncol. 10:669–678. 2017.
View Article : Google Scholar : PubMed/NCBI
|
